Is BioRestorative Therapies, Inc. (BRTX) a Buy, Sell, or Hold?
NASDAQ : BRTX
BioRestorative Therapies, Inc.
$0.2129 USD
$0.01 (5.92%)
- Volume
- 296.94K
- Average Volume
- 9.87M
- Market Capitalization
- $5.42M
- P/E Ratio
- -0.17
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $1.89
- Year Low
- $0.16
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.35
Company Overview
NASDAQ
Lance Alstodt
Biotechnology
Healthcare
BRTX
14
US
USD
Liquidity Metrics
0.01
2.35
2.35
1.93
0.00
Sales & Valuation
$359.7K
15.16
0.63
-0.46
-1.32
Profitability
-$1.58
-$14.24M
-3089.55%
-3089.55%
-423.84%
-238.27%
P/E Metrics
-0.17
-0.02
-0.02
Analyst Price Target & Rating
2/5
3 Analysts
%
Financial Health Scores
-58.46
2/9
$2.19M
$4.64M
$1.61M
-$11.06M
Key Metrics (TTM)
-$1.27M
-3.55
0.12
2.35
-423.84%
-464.86%
-611.67%
-658.24%
-8582 days
Company Executives
| Name | Title |
|---|---|
| Francisco J. Silva | VP of Research & Development, Secretary & Chief Scientist |
| Katharyn Field | President, CEO, Interim CFO, Treasurer & Secretary and Director |
| Lance Alstodt | Chairman of the Board, President & Chief Executive Officer |
| Robert Eugene Kristal | Chief Financial Officer |
| Crystal Romano | Head of Global Commercial Operations |
Poll Results
No votes yet today — be the first to share your view!
About BioRestorative Therapies, Inc. (NASDAQ:BRTX) Stock
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailmen ... ts by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
2026-06-25 08:15:00
MELVILLE, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX ), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced the successful completion of manufacturing for its BRTX-100 Phase 2 clinical trial, marking a key milestone in the development of its lead cell therapy candidate and underscoring the strength of the Company's vertically integrated regenerative medicine platform.
2026-06-18 08:15:00
Accomplished commercial aesthetics veteran to drive sales channel expansion and pipeline development MELVILLE, N.Y., June 18, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX ), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced the appointment of Zachary Smith as Vice President of its Biocosmeceuticals Division, further strengthening the Company's commercial leadership team as it expands its presence within the regenerative aesthetics and advanced skincare market.
Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)
2026-05-27 07:45:00
Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all shareholders MIAMI, May 27, 2026 /PRNewswire/ - Kaos Capital Ltd. ("Kaos Capital" or "we"), a Miami-based hedge fund focused on activist investing, today announced that it has acquired 4.9% of the issued and outstanding common stock of BioRestorative Therapies, Inc. ("BRTX" or the "Company").
2026-05-26 11:00:00
Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues Phase 3 readiness activities following FDA Type B meeting alignment
2026-05-26 11:00:00
Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues Phase 3 readiness activities following FDA Type B meeting alignment MELVILLE, N. Y. , May 26, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (Nasdaq:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced that the last patient has been dosed in its fully enrolled Phase 2 clinical trial evaluating BRTX-100 for the treatment of chronic lumbar disc disease (cLDD), completing treatment administration in the Company's lead clinical program and advancing the study into the next stage of blinded follow-up ahead of expected topline safety and efficacy data in Q2 2027.
What Makes Biorestorative Therapies (BRTX) a New Buy Stock
2026-05-15 13:01:19
Biorestorative Therapies (BRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates
2026-05-14 20:42:04
Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.56 per share a year ago.
2026-05-13 11:00:00
Data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and aesthetic applications
Frequently Asked Questions
-
What is the current BioRestorative Therapies, Inc. (BRTX) stock price?
-
BioRestorative Therapies, Inc.(NASDAQ:BRTX) stock price is $0.2129 in the last trading session. During the trading session, BRTX stock reached the peak price of $1.89 while $0.1593 was the lowest point it dropped to. The percentage change in BRTX stock occurred in the recent session was 5.92% while the dollar amount for the price change in BRTX stock was $0.01.
-
BRTX's industry and sector of operation?
-
The NASDAQ listed BRTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BRTX?
-
Francisco J. Silva | VP of Research & Development, Secretary & Chief Scientist
Katharyn Field | President, CEO, Interim CFO, Treasurer & Secretary and Director
Lance Alstodt | Chairman of the Board, President & Chief Executive Officer
Robert Eugene Kristal | Chief Financial Officer
Crystal Romano | Head of Global Commercial Operations -
How many employees does BRTX have?
-
Number of BRTX employees currently stands at 14. BRTX operates from 40 Marcus Drive, Melville, NY 11747, US.
-
Link for BRTX official website?
-
Official Website of BRTX is: https://www.biorestorative.com
-
How do I contact BRTX?
-
BRTX could be contacted at phone #631 760 8100 and can also be accessed through its website. BRTX operates from 40 Marcus Drive, Melville, NY 11747, US.
-
How many shares of BRTX are traded daily?
-
The average number of BRTX shares traded daily for last 3 months was 9.87M.
-
What is the market cap of BRTX currently?
-
The market value of BRTX currently stands at $5.42M with its latest stock price at $0.2129